login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock News
USA
- NASDAQ:OBIO -
US68572M1062
-
Common Stock
4.18
USD
-0.24 (-5.43%)
Last: 11/13/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OBIO Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
3 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
3 days ago - By: Zacks Investment Research
- Mentions:
CLSD
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
3 days ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
LGND
MDT
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
3 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
4 days ago - By: Zacks Investment Research
- Mentions:
ADCT
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
10 days ago - By: Zacks Investment Research
- Mentions:
ZYME
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed to Host Business Update Call on November 12, 2025
17 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
18 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
18 days ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
a month ago - By: Benzinga
- Mentions:
ONMD
ANVS
XBIO
PTGX
...
12 Health Care Stocks Moving In Friday's Intraday Session
a month ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
a month ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
MDT
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
2 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
2 months ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
MDT
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
3 months ago - By: Benzinga
- Mentions:
EPIX
WORX
THAR
NLSP
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
3 months ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
MDT
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
3 months ago - By: Zacks Investment Research
- Mentions:
GBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
3 months ago - By: Zacks Investment Research
- Mentions:
CRSP
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Pricing of $40 Million Public Offering
3 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Pricing of $40 Million Public Offering
4 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Proposed Public Offering
4 months ago - By: Orchestra BioMed Holdings, Inc.
Orchestra BioMed Announces Proposed Public Offering
4 months ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
LGND
MDT
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
4 months ago - By: Orchestra BioMed Holdings, Inc.
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
Please enable JavaScript to continue using this application.